Currently, there are 190.76M common shares owned by the public and among those 189.25M shares have been available to trade.
The company’s stock has a 5-day price change of 3.07% and -1.65% over the past three months. BMRN shares are trading -6.44% year to date (YTD), with the 12-month market performance down to -31.72% lower. It has a 12-month low price of $52.93 and touched a high of $94.85 over the same period. BMRN has an average intraday trading volume of 1.66 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -2.95%, -8.07%, and -14.21% respectively.
Institutional ownership of Biomarin Pharmaceutical Inc (NASDAQ: BMRN) shares accounts for 97.51% of the company’s 190.76M shares outstanding.
It has a market capitalization of $11.79B and a beta (3y monthly) value of 0.35. The stock’s trailing 12-month PE ratio is 27.96, while the earnings-per-share (ttm) stands at $2.20. The company has a PEG of 0.89 and a Quick Ratio of 3.29 with the debt-to-equity ratio at 0.11. Price movements for the stock have been influenced by the stock’s volatility, which stands at 3.04% over the week and 4.49% over the month.
Earnings per share for the fiscal year are expected to increase by 43.52%, and 29.75% over the next financial year.
Looking at the support for the BMRN, a number of firms have released research notes about the stock. Oppenheimer stated their Outperform rating for the stock in a research note on February 24, 2025, with the firm’s price target at $98. Wolfe Research coverage for the Biomarin Pharmaceutical Inc (BMRN) stock in a research note released on November 15, 2024 offered a Outperform rating with a price target of $95. William Blair was of a view on October 30, 2024 that the stock is Mkt Perform, while Raymond James gave the stock Outperform rating on October 10, 2024, issuing a price target of $79. Bernstein on their part issued Outperform rating on August 20, 2024.
